Ken Griffin Aligos Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $840 - $2,568	-2,400 Reduced 63.16%	1,400 $0
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $2,432 - $4,294	3,800 New	3,800 $3,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $7,031 - $10,744	-7,900 Reduced 62.7%	4,700 $4,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $4,785 - $11,605	5,500 Added 77.46%	12,600 $10,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $6,319 - $198,800	7,100 New	7,100 $6,000

47.3M

1.4K

300

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $326M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.